Building on a track record of more than 18 years’ experience in development work in the pharmaceutical and biotech industry, leading several projects to EMEA approval, Dr Savoy joined Biopartners in 2001 as Head of Pharma Development. Initially heading up Biopartners’ growth hormone development portfolio, he was promoted to Chief Scientific Officer working closely with Mr Treilles after the company was acquired by Bioton, and appointed to the board at the same time. Prior to joining Biopartners, Dr Savoy spent 10 years at Hoffmann-La Roche Ltd in various senior positions in global drug development. He holds an MBA from the Open University Business School, United Kingdom, and a PhD from the University of Basel, Switzerland.
“I am delighted to take on this new role and look forward to leading Biopartners in its next phase of development”, said Dr Savoy. “We are in a process of further consolidating our position within the Bioton Group by more closely integrating experience exchange and the transfer of best pharmaceutical practice across all Bioton Group companies. This will help maximize the opportunities for projects in development across the group, so that products reach the market in a timely fashion for the benefit of patients.”
In March 2009, Jean-Noël Treilles stepped down as CEO after five years service during which time he steered the company successfully through the acquisition by Bioton, together with Biopartners’ former Chief Financial Officer, Walter Häusermann.
